News
Recent news about Panacea Venture and select portfolio companies
TriArm Therapeutics Appoints Douglas E. Williams, Ph.D., as Chief Executive Officer
TriArm Therapeutics Appoints Douglas E. Williams, Ph.D., as Chief Executive Officer
CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He
CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He
Actym Therapeutics Expands Management Team with Key Appointments to Build Product Pipeline and Advance Clinical Development Strategies
Mary J. Janatpour, PhD, joins Actym as Chief Scientific Officer focused on expanding Actym’s pipeline Shouryadeep “Deep” Srivastava, MD, PhD, joins Actym as Senior Vice President of Clinical Development, leading Actym’s clinical activities BERKELEY, CA — June 25, 2024 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointments of […]
Actym Therapeutics Expands Management Team with Key Appointments to Build Product Pipeline and Advance Clinical Development Strategies
Mary J. Janatpour, PhD, joins Actym as Chief Scientific Officer focused on expanding Actym’s pipeline Shouryadeep “Deep” Srivastava, MD, PhD, joins Actym as Senior Vice President of Clinical Development, leading Actym’s clinical activities BERKELEY, CA — June 25, 2024 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointments of […]
DZD Presents at ASM Microbe
DZD Presents Direct-From-Blood, Rapid Antimicrobial Susceptibility Testing at the 2024 ASM Microbe conference
DZD Presents at ASM Microbe
DZD Presents Direct-From-Blood, Rapid Antimicrobial Susceptibility Testing at the 2024 ASM Microbe conference
Now Available: Myrtelle ASGCT Symposium Presentation
Myrtelle shared clinical trial updates and future directions for Oligodendrocyte targeting AAVs at the 27th Annual Meeting of the ASGCT.
Now Available: Myrtelle ASGCT Symposium Presentation
Myrtelle shared clinical trial updates and future directions for Oligodendrocyte targeting AAVs at the 27th Annual Meeting of the ASGCT.